Updated:
Creyon Bio
Creyon Bio is a family office investing in life sciences and therapeutics across 11 global offices including Boston, Shanghai, and Abu Dhabi.
Creyon Bio
Creyon Bio develops oligonucleotide-based medicines in the drug development industry. The company specializes in gene-centric therapies using antisense oligonucleotide technology for rare and common diseases. Founded in 2019, Creyon Bio is based in San Diego, California.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Shanghai, China · Herzliya, Israel · Abu Dhabi, UAE · Emeryville, CA, United States · Palo Alto, CA, United States · Berlin, Germany · South San Francisco, CA, United States · Atlanta, GA, United States · San Diego, CA, United States · Indianapolis, IN, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Creyon Bio?
No named principals are publicly disclosed for Creyon Bio. The office's leadership and decision-making structure remain confidential.
How does Creyon Bio source proprietary deal flow?
The firm's network of offices across Boston, Shanghai, Herzliya, and other major life sciences hubs suggests a locally sourced deal model. Each office likely taps into regional biotech ecosystems.
Is Creyon Bio structured as a single family office or does it operate more like a venture firm?
Public information describes Creyon Bio as a family office, but the absence of named principals or wealth origin details makes its exact structure unclear. Its multiple international offices are unusual for a single-family office.
Does Creyon Bio participate in fund commitments or only direct deals?
Its investment vehicles are not disclosed. The office's sector focus on biotech suggests it may engage in direct investments or co-investments.
What investment stages does Creyon Bio typically target?
The firm's focus on life sciences and therapeutics covers a range from drug discovery to clinical stages, but specific stage preferences are not public.
Which sectors does Creyon Bio explicitly avoid?
The firm's disclosed focus is solely on life sciences and therapeutics. Sectors outside biotech appear outside its mandate.
Where does the underlying wealth come from?
The wealth origin for Creyon Bio is not publicly disclosed. The family's source of capital remains private.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: